💊Takeda and HemoShear Therapeutics Enter into Exclusive Drug Discovery Partnership in Liver Diseases

JPN, Pharmaceutical

💊Kyowa Hakko Kirin Announces the Intent to File Istradefylline (KW-6002) for Parkinson’s Disease with the US FDA

FDA, JPN

💊Ono Enters into Exclusive License Agreement with Karyopharm to Develop and Commercialize Selinexor and KPT-8602, XPO1 Inhibitors  20171012

JPN, Pharmaceutical

💊TEIJIN | News | Teijin Signs Exclusive License and Co-Development Agreement for Novel Botulinum Toxin in Japan.

JPN, Pharmaceutical

💊Kyowa Hakko Kirin News、Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab’s Biologics License Application 20171010

FDA, JPN

Posts navigation